Genokey
PrecisionLife is a company dedicated to advancing precision medicine for complex chronic diseases through AI-driven insights, patient stratification, and novel target discovery. They focus on improving health outcomes, increasing drug success rates, and developing personalized diagnostic and therapeutic solutions. They utilize innovative methods such as Actively Protective Combinatorial Analysis to identify disease resilience and protective genetic variants, which can lead to new drug targets and improved patient stratification. Their work supports successful clinical development by discovering mechanism-based biomarkers, informing trial design, and enabling precision targeted clinical trials.
Industries
Products
Combinatorial analytics platform
A data analytics platform that detects high-order combinatorial genetic and phenotypic signatures, performs cohort stratification and supports pathway enrichment and target mapping.
Mechanism-based diagnostic tests (genotypic clinical assays)
Rapid, non-invasive mechanism-aligned tests designed to detect disease risk and mechanistic subtypes; validated biomarkers are translated into low-cost genotypic assays for clinical inclusion criteria and diagnostic use.
Clinical decision support (CDS) platform
Software to interpret mechanistic diagnostic results into clinical reports that enable triage, intervention prioritization and treatment selection.
Combinatorial Risk Scores (CRS)
Predictive risk models built from combinatorial disease signatures to estimate personal disease risk and subgroup-specific progression probabilities.
Combinatorial analytics platform
A data analytics platform that detects high-order combinatorial genetic and phenotypic signatures, performs cohort stratification and supports pathway enrichment and target mapping.
Mechanism-based diagnostic tests (genotypic clinical assays)
Rapid, non-invasive mechanism-aligned tests designed to detect disease risk and mechanistic subtypes; validated biomarkers are translated into low-cost genotypic assays for clinical inclusion criteria and diagnostic use.
Clinical decision support (CDS) platform
Software to interpret mechanistic diagnostic results into clinical reports that enable triage, intervention prioritization and treatment selection.
Combinatorial Risk Scores (CRS)
Predictive risk models built from combinatorial disease signatures to estimate personal disease risk and subgroup-specific progression probabilities.
Services
Precision drug discovery partnerships
Collaborative discovery services to identify and prioritize novel targets mapped to causal biology and to provide target data packages tailored to partner target product profiles.
Biomarker-driven clinical development support
Services to discover, validate and operationalize mechanistic biomarkers for trial enrichment, companion diagnostic strategy, regulatory engagement and patient recruitment.
Indication extension and repurposing analysis (precision repositioning)
Systematic analysis of target–patient subgroup biology to identify and prioritize indication extension and repurposing opportunities for existing drug candidates.
Combinatorial analytics platform access
Provision of analytics platform capabilities to detect high-order combinatorial signatures, build combinatorial risk score models, and perform cohort stratification and pathway analysis.
Clinical decision support deployment
Implementation of interpretation pipelines and clinical reporting to translate mechanism-based diagnostic results into triage and treatment recommendations.
Digital health & personalized advisory development (knowledge-graph driven)
Design and implementation of secure, personalized mobile advisory tools using compressed knowledge graphs of drug–disease–food interactions to deliver on-device recommendations.
Precision drug discovery partnerships
Collaborative discovery services to identify and prioritize novel targets mapped to causal biology and to provide target data packages tailored to partner target product profiles.
Biomarker-driven clinical development support
Services to discover, validate and operationalize mechanistic biomarkers for trial enrichment, companion diagnostic strategy, regulatory engagement and patient recruitment.
Indication extension and repurposing analysis (precision repositioning)
Systematic analysis of target–patient subgroup biology to identify and prioritize indication extension and repurposing opportunities for existing drug candidates.
Combinatorial analytics platform access
Provision of analytics platform capabilities to detect high-order combinatorial signatures, build combinatorial risk score models, and perform cohort stratification and pathway analysis.
Clinical decision support deployment
Implementation of interpretation pipelines and clinical reporting to translate mechanism-based diagnostic results into triage and treatment recommendations.
Digital health & personalized advisory development (knowledge-graph driven)
Design and implementation of secure, personalized mobile advisory tools using compressed knowledge graphs of drug–disease–food interactions to deliver on-device recommendations.
Expertise Areas
- Combinatorial genomic analytics and high-resolution patient stratification
- Mechanistic biomarker discovery, validation and clinical translation
- Precision drug target discovery and target–patient mapping
- Design and enrichment of biomarker-driven clinical trials
Key Technologies
- Combinatorial analytics for genomic data
- AI/ML-driven genomic and cohort analytics
- Combinatorial risk scoring
- Pathway enrichment and gene mapping